InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
58,028.42
(
-0.47%
)
Post# of 426487
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Biobillionair

Send PM Follow Ignore
Followers 234
Posts 26887
Boards Moderated 0
Alias Born 01/12/2013

Biobillionair

Re: None

Wednesday, 07/31/2013 7:55:46 AM

Wednesday, July 31, 2013 7:55:46 AM

Post# of 426487
History of last meeting.

Fall of 2012 :AMRN, GSK Amarin Vascepa has blockbuster potential, says Roth Capital
Roth Capital believes that Amarin's (AMRN) Vascepa for patients with elevated triglycerides has a differentiated profile from GlaxoSmithKline's (GSK) Lovaza. The firm thinks that Vascepa has a very benign adverse event profile but it lowered its target on Amarin to $17 from $26 to reflect greater commercial and competitive risks. However, the firm maintains a Buy rating on the stock.
-------
Roth's basis of today's meeting was IP, it was scheduled after Vascepa's Epanova Patent test FAILURE.

Expect analysts to start to include anchor in projections soon. Just multiple by 10;)

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News
InvestorsHub NewsWire

Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM

Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM

EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM

BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM

NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM

Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM

Start posting your company's news
Only $200 per official company press release!